Medical innovators blinktbi, Inc., has hired Jeff Riley as its Chief Executive Officer to its Board of Directors. Mr. Riley replaces founding CEO Dr. Doug Carnes, who will continue to serve as a Member on the Board of Directors and Chief Operating Officer.
"As we align our proprietary EyeStat technology platform with an expanded clinical focus, Jeff's proven leadership, focused vision, and ability to bring the right people together make him the ideal person to lead our company during this transition," said Dr. Carnes. "Jeff's considerable clinical and corporate development experience will be instrumental in shaping blinktbi for its next chapter of product innovation and growth. I'm excited to be staying on as Chief Operations Officer and look forward to working with Jeff and the blinktbi team to advance our shared vision for the future of our company."
Mr. Riley brings more than a quarter of a century of pharmaceutical and biotechnology leadership experience to blinktbi. He has held senior positions at SmithKline Beecham, Pfizer, Quest Diagnostics, Xenome and Ontogen, as well as his most recent position as CEO, President and Director at Synthetic Biologics.
"Blinktbi is on the forefront of one of the most exciting and disruptive technologies capable of detecting changes in the trigeminal nerve and the way certain neurological disorders are diagnosed, monitored and treated," said Mr. Riley. "The company has a solid infrastructure in place with a compelling vision, great people and innovative FDA-cleared technology supported by foundational research. I am excited to lead blinktbi into the next stage of development, which includes building a strong clinical component to support expansion into new markets and clinical applications."